BlackRock
CERE

BlackRock’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

BlackRock’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,560,931
Closed -$146M – 5391
2024
Q2 		$146M Sell
3,560,931
-1,887,689
-35% -$78.6M ﹤0.01% 1802
2024
Q1 		$230M Sell
5,448,620
-578,905
-10% -$24.3M 0.01% 1556
2023
Q4 		$256M Buy
6,027,525
+1,036,499
+21% +$29.8M 0.01% 1488
2023
Q3 		$109M Buy
4,991,026
+158,319
+3% +$3.96M ﹤0.01% 1939
2023
Q2 		$154M Buy
4,832,707
+347,766
+8% +$10.7M ﹤0.01% 1772
2023
Q1 		$109M Buy
4,484,941
+2,678
+0.1% +$78.6K ﹤0.01% 1957
2022
Q4 		$141M Buy
4,482,263
+293,892
+7% +$8.29M ﹤0.01% 1767
2022
Q3 		$118M Buy
4,188,371
+56,084
+1% +$1.67M ﹤0.01% 1853
2022
Q2 		$109M Buy
4,132,287
+740,872
+22% +$21M ﹤0.01% 1948
2022
Q1 		$119M Sell
3,391,415
-93,242
-3% -$2.72M ﹤0.01% 2028
2021
Q4 		$113M Buy
3,484,657
+121,379
+4% +$4.28M ﹤0.01% 2138
2021
Q3 		$99.2M Buy
3,363,278
+710,720
+27% +$20M ﹤0.01% 2219
2021
Q2 		$68M Buy
2,652,558
+1,554,987
+142% +$22.3M ﹤0.01% 2493
2021
Q1 		$15.1M Buy
1,097,571
+2,180
+0.2% +$31.9K ﹤0.01% 3340
2020
Q4 		$18.2M Buy
+1,095,391
New +$14.2M ﹤0.01% 3056

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

BlackRock's CERE Position: Q3 2024 in Review

BlackRock sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 3,560,931 shares — an estimated $146M sold.

BlackRock first reported a position in CERE in Q4 2020 and held it in 15 quarters. The position peaked at $256M in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • BlackRock reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • BlackRock sold 3,560,931 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $146M.
  • BlackRock first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 15 quarters.
  • BlackRock's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $256M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on BlackRock's 13F filing for Q3 2024, filed 13 Nov 2024.